# A Study of BGB-11417 in Participants With Myeloid Malignancies

Source: https://onco.cc/trials/nct04771130/  
OnCo record `nct04771130` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Sonrotoclax and Azacitidine in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by BeOne Medicines, now recruiting.

## Summary

A Study of BGB-11417 in Participants With Myeloid Malignancies is a phase 1/2 interventional study registered as NCT04771130 by BeOne Medicines, with 260 participants planned, started 2021-05-24 and due to reach its primary completion in 2028-08-31. Interventions recorded: BGB-11417, Azacitidine and Posaconazole.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04771130
- Phase: 1/2
- Setting: A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies
- Sponsor: BeOne Medicines
- Enrolled: 260

## Sources

- ClinicalTrials.gov NCT04771130: https://clinicaltrials.gov/study/NCT04771130

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Sonrotoclax](https://onco.cc/drugs/sonrotoclax/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)

---
JSON: https://onco.cc/api/v1/entities/nct04771130.json